All In Biotech

Drug Trial Radar · NCT04977453

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

A Phase 1/2, Open-label, Dose-escalation, Dose-optimization and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Therapeutic Activity of GI-101/GI-101A as a Single Agent and in Combination With Pembrolizumab or Lenvatinib in Patients With Advanced or Metastatic Solid Tumors (Keynote B59)

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 317 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

317

Planned (sponsor's estimate)

Start

Aug 2, 2021

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
GI Innovation, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Cervical Cancer
  • Urothelial Carcinoma
  • Clear Cell Renal Cell Cancer (ccRCC)
  • Squamous Cell Non Small Cell Lung Cancer

Interventions

  • GI-101Drug

    Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

  • Pembrolizumab (KEYTRUDA®)Drug

    Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

  • LenvatinibDrug

    Lenvatinib will be administered at an approved dose orally.

  • GI-101ADrug

    Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and nature of Dose-Limiting Toxicity (DLTs), Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs)Time frame: Study Day 1, assessed up to approximately 24 months
  2. Objective Response Rate (ORR), Disease Control Rate (DCR) and Duration of Response (DoR) according to RECIST version 1.1Time frame: Study Day 1, assessed up to approximately 24 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Tisch Cancer Institute (TCI), Icahn School of Medicine

    New York, New York · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Carolina Biooncology Institute

    Huntersville, North Carolina · Recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • The Catholic University of Korea Seoul ST.MARY'S Hospital

    Seoul, Banpo-daero, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seoul, Bundang-gu, South Korea · Recruiting

  • Chungnam National University Hospital

    Daejeon, Daejeon, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, Gangnam, South Korea · Recruiting

  • The Catholic University of Korea St. Vincent's Hospital

    Suwon, Kyeonggi-do, South Korea · Recruiting

  • Korea University Anam Hospital

    Seoul, Seongbuk-gu, South Korea · Recruiting

  • Ewha Womans University Mokdong Hospital

    Seoul, Yangcheon-gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.